Novartis Claims Starlix Safety, Post-Meal Benefit For Its First Diabetes Drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis is describing Starlix as having a superior safety profile to other oral drugs that target postprandial glucose levels (PPG) in patients with type 2 diabetes mellitus.